Excited to share some remarkable accomplishments from Medcura, Inc., a medical technology company in the Propel(x) portfolio. Medcura develops advanced bioactive surgical implants that actively control bleeding and reduce complications during surgery.
Key achievements from 2024–2025 include:
• FDA Breakthrough Device Designation for LifeGel™ Absorbable Hemostatic Gel, recognizing its potential to improve bleeding control in sensitive surgical environments, including spine surgery.
• Industry recognition as LifeGel™ received the Best Technology in Spine Award, highlighting its innovation and clinical impact.
• Formation of a world-class Spinal Surgery Advisory Board, bringing together leading surgeons to guide clinical strategy and adoption.
• Leadership recognition with CEO Jim Buck named a 2025 EY Entrepreneur Of The Year® Mid-Atlantic Award Finalist.
• Expanded FDA 510(k) clearances across Medcura’s hemostatic and wound care product portfolio, strengthening its presence in both clinical and consumer markets.
Medcura’s continued progress reflects the power of focused innovation and strong execution in advancing patient care. We’re excited to support their journey as they build the future of surgical hemostasis.
Be part of the next wave of innovation; invest through Propel(x):www.propelx.com
Startups – Get listed on Propel(x): app.propelx.com/raise
